ZETAMET

Serial Number 97054481
807

Registration Progress

Application Filed
Sep 30, 2021
Under Examination
Sep 27, 2022
Approved for Publication
Aug 2, 2022
Published for Opposition
Aug 2, 2022
Registered

Trademark Image

ZETAMET

Basic Information

Serial Number
97054481
Filing Date
September 30, 2021
Published for Opposition
August 2, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
807
Status Date
Sep 29, 2025
Application
Pending
Classes
005

Rights Holder

Zetagen Therapeutics, Inc.

03
Address
841 East Fayette Street
Syracuse, NY 13210

Ownership History

Zetagen Therapeutics, Inc.

Original Applicant
03
Syracuse, NY

Zetagen Therapeutics, Inc.

Owner at Publication
03
Syracuse, NY

Legal Representation

Attorney
Katherine P. Califa

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

36 events
Date Code Type Description Documents
Sep 29, 2025 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 29, 2025 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Sep 29, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 26, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Sep 25, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Sep 25, 2025 IUAF S USE AMENDMENT FILED Loading...
Jul 12, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 11, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 11, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 23, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Aug 21, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Aug 21, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 21, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Aug 21, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 21, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 20, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 20, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 20, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 7, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 16, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 14, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 14, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 14, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 11, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 9, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 9, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 9, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 27, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 2, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 2, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 13, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 30, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 30, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 28, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 4, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of metastatic tumors and lesions; Pharmaceuticals, namely, for destroying, inhibiting or preventing the spread of uncontrolled growth of abnormal tissues, namely, metastatic tumors and lesions
First Use Anywhere: Sep 25, 2025
First Use in Commerce: Sep 25, 2025

Classification

International Classes
005